Success Metrics

Active Trials
2(33%)

Phase Distribution

Ph phase_2
4
67%
Ph phase_1
1
17%
Ph phase_3
1
17%

Phase Distribution

1

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
4(66.7%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Other(1)

Detailed Status

Not yet recruiting3
unknown1
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 24 (66.7%)
Phase 31 (16.7%)

Trials by Status

unknown117%
not_yet_recruiting350%
recruiting117%
active_not_recruiting117%

Recent Activity

2 active trials
Showing 5 of 6
not_yet_recruitingphase_1

A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT07570017
recruitingphase_3

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

NCT07409428
not_yet_recruitingphase_2

Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT07122609
active_not_recruitingphase_2

Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

NCT06601504
not_yet_recruitingphase_2

AZA Combined with R-GemOx for Elderly DLBCL Patients

NCT06778902
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07570017Phase 1

A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Not Yet Recruiting
NCT07409428Phase 3

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Recruiting
NCT07122609Phase 2

Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Not Yet Recruiting
NCT06601504Phase 2

Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Active Not Recruiting
NCT06778902Phase 2

AZA Combined with R-GemOx for Elderly DLBCL Patients

Not Yet Recruiting
NCT01670370Phase 2

Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6